Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle

Cytokinetics Incorporated CYTK presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM).
At ten weeks, patients in Cohort 4 experienced significant improvements in NT-proBNP, with an average decrease of 66%.
High-sensitivity troponin I level also improved significantly proportional to baseline at each study visit.
Related: FDA Rejects Cytokinetics' Heart Failure Treatment Candidate.
An improvement of ≥1 NYHA Functional Class was observed in 22 of 41 (54%) patients.
After the 2-week washout period, NT-proBNP and high-sensitivity troponin I levels returned to baseline.
Additionally, 48-week data from the FOREST-HCM study were also presented at the meeting.
New data through 48 weeks of treatment showed that aficamten was associated with significant reductions in the average resting LVOT-G (mean change from baseline (SD) = -32 (28) mmHg, and Valsalva LVOT-G (mean change from baseline (SD) = -47 (28) mmHg.
Treatment with aficamten also resulted in significant improvements in NYHA class, with 88% of patients experiencing a ≥1 NYHA Functional Class improvement, and significant improvements in NT-proBNP, with an average decrease of 70% from baseline to Week 48.
Price Action: CYTK shares closed at $41.95 on Friday.